Corvus Pharmaceuticals (CRVS) investor relations material

Company overview and lead program

• Focuses on novel immune modulators for cancer and immune diseases, with soquelitinib as the lead oral ITK inhibitor in phase III for PTCL and phase II for atopic dermatitis.

• Soquelitinib is also being studied in China by a partner and will expand into asthma and HS trials this year.

• Strong patent protection extends to 2042 with pharmaceutical extensions.

• ITK platform supports a pipeline of next-generation and backup compounds.

Mechanism of action and differentiation

• Soquelitinib is an oral tablet, offering an alternative to injectable therapies in atopic dermatitis.

• Blocks Th2 and Th17 pathways, reducing key cytokines and increasing Treg cells, rebalancing rather than suppressing the immune system.

• Highly selective for ITK, with limited off-target effects and a strong safety profile.

• No observed immunosuppression or infection risk due to sparing of RLK pathway.

Clinical and biomarker data

• Safety profile in atopic dermatitis is similar to placebo; efficacy is comparable to JAK inhibitors or biologics depending on endpoint.

• Biomarker data show dose-dependent reduction in Th2/Th17 cytokines and increased Treg cells, with effects persisting off therapy.

• Clinical effect maintained up to 90 days post-therapy; durability to be further studied in ongoing trials.